Resources

Novo Nordisk is turning to stem cells in the hunt for a cure for diabetes by launching a new collaboration to develop a treatment for type 1 diabetes by programming stem cells to turn into insulin-producing cells.

End-stage renal disease rates rose following widespread introduction of high fructose corn syrup in the American diet, supporting speculation that fructose harms the kidney.

Adjunct metformin treatment was associated with sustained reductions of insulin dose and body weight for Type 1’s.

Novel insulin formulation provides for glucose-regulated insulin delivery.

Dave Kliff, Publisher of Diabetes Investor, recently reviewed the last remaining inhaled insulin in development and has some interesting information. It looks like the hardest part of making it work will be who sells it. Make sure you read, Buying Into The Dream

Dr. Sheri Colberg, Ph.D., FACSM, knows that some of our patients can barely do anything and she has a couple of activities that almost anyone can do. Two Easy Resistance Exercises That Build Basic Functional Strength will work for every one of our patients.

In a head to head trial (LEAD 6), it showed that liraglutide, a human GLP-1 analog administered once daily was significantly more effective at improving blood glucose control (as measured by HbA1c) than exenatide, a GLP-1 mimetic administered twice daily.

A 2-day in-hospital group program of diabetes education, followed by individual support sessions every 3 months, significantly helped prevent or delay progression to type 2 diabetes in patients with impaired glucose tolerance.

At-risk individuals with an HbA1c test level of 5.4% or greater can signal undiagnosed diabetes and certainly prediabetes, according to new study findings.

Gastric bypass (GBP) surgery is an effective way for most patients to lose weight, but poor results are associated with diabetes and larger gastric pouch size, according to the results of a prospective cohort study.